Avidity Biosciences (RNA) Price & Analysis

Compare

1,103 Followers

RNA Stock Chart & Stats

$71.63

-$0.39(-1.27%)

At close: Jan 08 4:00 PM EST

$71.63

-$0.39(-1.27%)

Day’s Range― - ―

52-Week Range$21.51 - $71.79

Previous CloseN/A

Volume185.29K

Average Volume (3M)7.81M

Market Cap

$10.79B

Enterprise Value$4.18B

Total Cash (Recent Filing)$1.88B

Total Debt (Recent Filing)$49.97M

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Mar 03, 2026

EPS Estimate

-1.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding150,675,740

10 Day Avg. Volume2,011,221

30 Day Avg. Volume7,814,035

Financial Highlights & Ratios

PEG Ratio14.65

Price to Book (P/B)2.28

Price to Sales (P/S)297.77

P/FCF Ratio-10.54

Enterprise Value/Market Cap0.39

Enterprise Value/Revenue200.41

Enterprise Value/Gross Profit-35.67

Enterprise Value/Ebitda-7.03

Forecast

1Y Price Target

$71.71

Price Target Upside0.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

EPS Forecast (FY)-4.41

Revenue Forecast (FY)$17.60M

Bulls Say, Bears Say

Bulls Say

Acquisition PremiumNovartis' bid represents a 46% premium to Friday's closing stock price of $49.15 on October 24th, 2025, and a 62% premium to the 30-day VWAP of $44.42.

Pipeline PotentialRNA's pipeline is seen as having upside value due to the strength of clinical benefit, likelihood of approval, and rapidity of their path to market.

Strategic ExpansionThe acquisition underscores Novartis’ strategic intent to expand its neuroscience and rare disease portfolio, anchored by Avidity’s late-stage AOC pipeline.

Bears Say

Investment RisksRisks to the investment thesis include the failure of Del-desiran, Del-brax, Del-zota in clinical studies and to secure regulatory approval in the US and EU.

Net LossRNA reported a 3Q25 net loss of $174.4M.

Rating DowngradeThe recommendation has been downgraded to Hold and the price target decreased to $74.

Avidity Biosciences News

Avidity Biosciences reports Q3 EPS ($1.27), consensus ($1.10)

Reports Q3 revenue $12.5M, consensus $1.81M. Expects that its cash, cash equivalents and marketable securities as of September...

28d ago

RNA

Hold Rating on Avidity Biosciences Amid Novartis Acquisition and Strategic Developments

In a report released yesterday, Ritu Baral from TD Cowen maintained a Hold rating on Avidity Biosciences, with...

27d ago

RNA

Hold Rating on Avidity Biosciences Amid Novartis Acquisition Uncertainty

Needham analyst Joseph Stringer has maintained their neutral stance on RNA stock, giving a Hold rating on October...

27d ago

RNA

Avidity Biosciences Reports Increased Revenue Amid Losses

Avidity Biosciences Inc ( ($RNA) ) has released its Q3 earnings. Here is a breakdown of the information...

27d ago

RNA

RNA Earnings this Week: How Will it Perform?

Avidity Biosciences Inc (RNA) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

29d ago

RNA

Avidity Biosciences downgraded to Hold from Buy at TD Cowen

TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of...

1M ago

RNA

Hold Rating Issued Amid Avidity Biosciences Acquisition and Strategic Restructuring

TD Cowen analyst Ritu Baral downgraded the rating on Avidity Biosciences to a Hold today, setting a price...

1M ago

RNA

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

NVS

Avidity Biosciences downgraded to Neutral from Buy at Citi

Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of...

1M ago

RNA

Avidity Biosciences downgraded to Neutral from Buy at Chardan

Chardan analyst Keay Nakae downgraded Avidity Biosciences (RNA) to Neutral from Buy with a $72 price target after...

1M ago

RNA

Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded Avidity Biosciences (RNA) to Sector Perform from Outperform with a price target of $72, up...

1M ago

RNA

Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations

The major averages were sharply higher near noon as the market appears to exude new optimism amid fresh...

1M ago

Avidity Biosciences rises 42.5%

Avidity Biosciences (RNA) is up 42.5%, or $20.88 to $70.03. Published first on TheFly – the ultimate source...

1M ago

RNA

Avidity Biosciences downgraded to Neutral from Buy at Citi

Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of...

1M ago

RNA

RNA FAQ

What was Avidity Biosciences Inc’s price range in the past 12 months?

Avidity Biosciences Inc lowest stock price was $21.51 and its highest was $71.79 in the past 12 months.

What is Avidity Biosciences Inc’s market cap?

Avidity Biosciences Inc’s market cap is $10.79B.

When is Avidity Biosciences Inc’s upcoming earnings report date?

Avidity Biosciences Inc’s upcoming earnings report date is Mar 03, 2026 which is in 85 days.

How were Avidity Biosciences Inc’s earnings last quarter?

Avidity Biosciences Inc released its earnings results on Nov 10, 2025. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$1.085 by -$0.185.

Is Avidity Biosciences Inc overvalued?

According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avidity Biosciences Inc pay dividends?

Avidity Biosciences Inc does not currently pay dividends.

What is Avidity Biosciences Inc’s EPS estimate?

Avidity Biosciences Inc’s EPS estimate is -1.22.

How many shares outstanding does Avidity Biosciences Inc have?

Avidity Biosciences Inc has 150,675,740 shares outstanding.

What happened to Avidity Biosciences Inc’s price movement after its last earnings report?

Avidity Biosciences Inc reported an EPS of -$1.27 in its last earnings report, missing expectations of -$1.085. Following the earnings report the stock price went up 1.231%.

Which hedge fund is a major shareholder of Avidity Biosciences Inc?

Currently, no hedge funds are holding shares in RNA

Avidity Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-32.44%

Trailing 12-Months

Asset Growth

30.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences (RNA) Earnings & Revenues

Historic Earnings Reports

RNA Stock 12 Month Forecast

Average Price Target

$71.71

▲(0.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,71.86153846153846,73.87307692307692,75.88461538461539,77.89615384615384,79.9076923076923,81.91923076923077,83.93076923076923,85.9423076923077,87.95384615384614,89.96538461538461,91.97692307692307,93.98846153846154,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,69.99307692307691,70.13615384615385,70.27923076923076,70.42230769230768,70.56538461538462,70.70846153846153,70.85153846153845,70.99461538461537,71.1376923076923,71.28076923076922,71.42384615384614,71.56692307692308,{"y":71.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,68.55384615384615,67.25769230769231,65.96153846153845,64.66538461538461,63.36923076923077,62.07307692307692,60.776923076923076,59.480769230769226,58.184615384615384,56.888461538461534,55.59230769230769,54.29615384615384,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >